Live
FierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and ChinaEndpoints NewsSupreme Court restores mifepristone access by mailClinical OMICsBiomarker of Epigenetic Aging Could Signal DepressionAmgenPfizer vs. Amgen: Which Big Pharma Stock Is the Better Value Right Now? - TIKR.comFierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 winSamsung BiologicsCDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike - Fierce PharmaNovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce PharmaFierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQviaBioWorldBiggest gainers and losers for April 27-May 1, 2026Endpoints NewsCelcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series AAmgenGuggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge? - 24/7 Wall St.FierceBiotechWindward catches $165M breeze to fuel long-acting TSLP ambitions
This story is not available in the archive.